Chennai, India | February 19, 2015

Financial highlights for Quarter ended December 31, 2014 (Q5 FY15) - Standalone

Revenue of Rs 164.54 crore (US$ 26.1 million) in the quarter ended December 31, 2014 (Q5 FY14) as compared to Rs 371.60 crore (US$ 58.9 million) registered during the corresponding quarter ended December 31, 2013.

* 1 US$ = Rs 63.03

The company has extended its current financial and accounting year by six months to March 31, 2015. This is to fall in line with the new Companies Act requirement.

The Company has obtained approval from "LAGeSo Berlin", an European Regulatory Authority for Good Manufacturing Practices (GMP) in November 2014 for its Alathur API manufacturing facility.

From the Managing Director

"With the availability of working capital in place, the Company is currently stabilizing itself in the market through increased production and sales level.  We are confident that the Company would reach optimum production/sales levels from the first quarter of the financial year 2015-16 and the efforts of the Company for achieving this are on track", said Mr K Raghavendra Rao, Managing Director, Orchid Chemicals & Pharmaceuticals Ltd.

distributed by